Edition:
India

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

5.21USD
17 Nov 2017
Change (% chg)

$-0.06 (-1.14%)
Prev Close
$5.27
Open
$5.20
Day's High
$5.31
Day's Low
$5.12
Volume
59,340
Avg. Vol
45,483
52-wk High
$10.86
52-wk Low
$2.93

Latest Key Developments (Source: Significant Developments)

Oncomed posts Q3 loss per share $0.28
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Oncomed Pharmaceuticals Inc :Oncomed announces third quarter 2017 financial results and operational highlights.Q3 loss per share $0.28.Q3 revenue $5.1 million versus $5.9 million.Oncomed Pharmaceuticals Inc - ‍anticipates 2017 full-year cash utilization will be approximately $90 million​.Oncomed says current cash balance sufficient to fund pipeline development & operations through Q3 2019, before considering potential opt-in milestones​.Oncomed Pharmaceuticals - ‍now plans to initiate Phase 1B portion of anti-tigit trial to study anti-tigit in combination with anti-PD1 in H1 2018​.  Full Article

BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals - SEC filing
Friday, 26 Aug 2016 

BVF Inc:BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals as of Aug. 18, 2016 - SEC filing.  Full Article

Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 24 Aug 2016 

Oncomed Pharmaceuticals :Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing.  Full Article

OncoMed Pharmaceuticals prices public offering of common stock
Thursday, 18 Aug 2016 

OncoMed Pharmaceuticals Inc : OncoMed Pharmaceuticals announces pricing of public offering of common stock .Says public offering of 5.50 million common shares priced at $10.00 per share.  Full Article

Oncomed Pharmaceuticals announces proposed public offering of common stock
Thursday, 18 Aug 2016 

Oncomed Pharmaceuticals Inc : Oncomed Pharmaceuticals announces proposed public offering of common stock .To use net proceeds from offering for general corporate purposes, increasing working capital, funding research development.  Full Article

Oncomed pharmaceuticals reports Q2 2016 financial results
Wednesday, 10 Aug 2016 

Oncomed Pharmaceuticals Inc : Oncomed pharmaceuticals reports second quarter 2016 financial results .Q2 loss per share $0.91.  Full Article

OncoMed provides update on tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
Monday, 25 Jan 2016 

OncoMed Pharmaceuticals Inc:Announces an update on the Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data safety monitoring board (DSMB).No unexpected safety findings emerged from its review.Says eighteen patients remain on study drug treatment (tarextumab or placebo) between 172 and 527 days.  Full Article

BRIEF-Oncomed posts Q3 loss per share $0.28

* Oncomed announces third quarter 2017 financial results and operational highlights